Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB011 + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- CARsgen Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AB011 + capecitabine + oxaliplatin is an investigational combination regimen developed for the treatment of advanced gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma. The combination consists of AB011, a recombinant humanized IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2), capecitabine (an oral fluoropyrimidine prodrug that is converted to 5-fluorouracil in vivo and inhibits DNA synthesis), and oxaliplatin (a platinum-based chemotherapeutic that induces DNA cross-linking and apoptosis). AB011 enhances antitumor efficacy via immune-mediated mechanisms of action directed at CLDN18.2, which is overexpressed in various solid tumors, particularly gastric cancers. Preclinical and clinical data demonstrate synergistic effects between AB011 and cytotoxic agents, with the combination showing early clinical benefit, manageable safety, and high objective response rates in Phase I studies.
- Other names
- CAPOX
02
Targets
Claudin 18.2TS (Thymidylate synthase)
Beyond the preview
Go deeper on AB011 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB011 + capecitabine + oxaliplatin.